20-Antibody Cocktail for B-ALL Immunophenotyping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current flow cytometry methods for immunophenotyping B lymphoblastic leukemia/lymphoma require multiple tubes and antibodies, leading to high costs, complexity, and reduced accuracy due to the need for repeated gating antibodies and variability in antibody quality and expression, which complicates the detection of 20-30 types of antibodies needed for accurate diagnosis and treatment.
Innovation Solution
A reagent composition comprising 20 antibodies, including CD20, CD21, CD25, CD66, CD13, and CD38, is designed to be used in a single-tube combination, allowing for simultaneous detection of multiple markers and reducing the number of tubes needed, thereby improving detection efficiency and accuracy, and enabling better prediction of Ph+ALL and other subtypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple tubes and antibodies are used for immunophenotyping, then the detection coverage increases, but the device complexity and operation complexity increase
Solution Approach 1:
The patent combines multiple antibody detections into a single tube by using a cocktail approach where 2-8 different antibodies are mixed together in one reagent tube. This merging of multiple detection functions into one tube reduces the total number of tubes needed while maintaining comprehensive detection coverage for B-ALL/LBL immunophenotyping.
Solution Approach 2:
The reagent composition is designed to be universal for detecting multiple B-cell markers simultaneously. The antibody cocktail can detect various differentiation stages (pro-B, pre-B, common-B) and genetic abnormalities (Ph+, hyperdiploidy, etc.) in a single assay, making the reagent system multi-functional for different diagnostic purposes.
2Measurement precision
If multiple antibodies are used for immunophenotyping, then the detection accuracy improves, but the cost increases
Solution Approach 1:
By combining multiple antibodies into a single reagent tube, the patent reduces the total number of separate reagent purchases and handling steps. Although multiple antibodies are used, the consolidated approach in one tube reduces overall cost compared to using separate tubes for each antibody detection.
Solution Approach 2:
The patent optimizes the antibody cocktail composition by selecting specific antibodies with appropriate fluorescence markers that can be detected simultaneously. This parameter optimization ensures high detection accuracy while controlling costs through efficient use of reagents and reduced sample consumption.
3Adaptability or versatility
If multiple tubes are used for immunophenotyping, then the detection comprehensiveness improves, but the operation time increases
Solution Approach 1:
The patent merges multiple detection steps into a single tube assay, allowing simultaneous detection of multiple B-cell markers in one incubation and washing cycle. This eliminates the need to process multiple tubes sequentially, significantly reducing operation time while maintaining comprehensive detection of immunophenotypic features.
4Reliability
If repeated gating antibodies are used, then the detection reliability improves, but the variability in antibody quality affects accuracy
Solution Approach 1:
The patent uses a standardized antibody cocktail with consistent fluorescence markers and predetermined ratios of different antibodies. This homogenization of the reagent composition reduces variability between experiments and operators, improving both reliability and precision by eliminating the need for repeated gating with different antibodies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The 20-antibody combination significantly improves the accuracy and sensitivity of B lymphoblastic leukemia/lymphoma immunophenotyping, with a predictive positive rate of 92.86% and specificity of 90.0% for Ph+ALL, and reduces the need for multiple tubes and operation steps, enhancing clinical detection and treatment decision-making.
Implementation Method 1
A reagent composition comprising 20 antibodies, including CD20, CD21, CD25, CD66, CD13, and CD38, is designed to be used in a single-tube combination, allowing for simultaneous detection of multiple markers
Data Source
AI summary
Provided is a reagent composition for immunophenotyping and MRD monitoring of B lymphoblastic leukemia/lymphoma (B-ALL/LBL). The reagent composition includes a 20-antibody combination. In the present disclosure, the antibody combination, the fluorescent labeling combination for the corresponding antibody, and the result interpretation methods are optimized. It only needs to use 20 kinds of antibodies in a single tube of cells for one sample loading, allowing for comprehensively and efficiently performing subtype typing on B lymphoblastic leukemia/lymphoma. In addition, it enables to predict part of recurrent genetically abnormal B-ALL/LBL and has high sensitivity and specificity for the diagnosis of the subtype of BCR/ABL1 gene. Meanwhile, it enables to determine the leukemia-related immunophenotype (LAIP) for minimal residual disease (MRD) monitoring after treatment by using the combination and used for MRD monitoring and CAR-T post-treatment monitoring.